Hemocompatibility testing, formally known as the evaluation of interactions between medical devices and blood, is a critical component of the biological safety assessment required for any device that contacts circulating blood. Guided primarily by ISO 10993-4, these studies assess thrombosis, coagulation, platelet function, hematology, and complement activation to support regulatory submissions worldwide. This article provides a comprehensive technical overview of blood-device interaction testing, including applicable sample types, test items, methodologies, and frequently asked questions.
Technical Overview
Hemocompatibility testing evaluates the adverse interactions that may occur when blood comes into contact with the materials and surfaces of medical devices. Because blood is biologically programmed to respond to foreign surfaces, device contact can trigger thrombus formation, activation of the coagulation cascade, platelet adhesion and activation, hemolysis, leukocyte changes, and activation of the complement system. The primary framework for this evaluation is ISO 10993-4, Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood, which is applied together with ISO 10993-1 for test selection, ISO 10993-12 for sample preparation, and complementary ASTM standards such as ASTM F756 for hemolysis testing.
ISO 10993-4 organizes testing around five interaction categories: thrombosis, coagulation, platelets, hematology, and the complement system. The required scope of testing is determined by the nature and duration of blood contact, and testing may be performed using in vitro, in vivo, or ex vivo approaches.
- Device contact categories: external communicating devices with indirect blood contact (for example, cannulae and infusion sets), external communicating devices in the circulating blood path (for example, hemodialysis circuits and intravenous catheters), and implant devices (for example, vascular grafts and stents).
- Contact duration categories: limited contact (24 hours or less), prolonged contact (24 hours to 30 days), and permanent contact (more than 30 days).
- Test strategy: at least one test from the applicable interaction categories is selected based on the device category, contact duration, and the overall biological evaluation plan.
Regulatory authorities in major jurisdictions, including the United States, the European Union, China, and Japan, expect documented hemocompatibility data as part of biological safety files for blood-contacting devices. Accredited third-party laboratories routinely perform these studies under GLP or ISO/IEC 17025 quality systems to support submissions such as FDA 510(k), PMA, EU MDR CE marking, and NMPA registration.
Testing Samples
Indirect Blood Contact Devices
Devices that contact blood at the point of use but do not remain in the circulating blood stream represent the broadest category of samples. Typical examples include hypodermic needles, syringes, intravenous infusion sets and administration sets, winged blood collection needles, lancets, and blood collection tubes. For these devices, in vitro assays such as hemolysis, partial thromboplastin time, and complement activation are typically the primary evaluation tools.
Circulating Blood Contact Devices
Devices through which blood flows and returns to the patient require more extensive evaluation. Representative samples include hemodialyzers, extracorporeal circuit tubing sets, blood oxygenators for cardiopulmonary bypass, apheresis kits, intravenous and arterial catheters, percutaneous endovascular delivery systems, blood bags, and blood pumps. Testing for these devices frequently includes dynamic flow models that simulate clinical shear conditions.
Implantable Blood-Contacting Devices
Long-term and permanent implants in the vascular system carry the highest thrombotic risk profile. Samples include vascular grafts and patches, coronary and peripheral stents, heart valve prostheses, inferior vena cava filters, pacemaker and defibrillator leads, septal occluders, ventricular assist devices, and artificial hearts. These devices often require in vivo or ex vivo thrombogenicity assessment in addition to in vitro testing.
Materials, Coatings, and Extracts
In addition to finished devices, testing can be performed on candidate polymers, metals, ceramics, surface coatings such as heparinized or hydrophilic coatings, adhesives, and process fluids. Samples are prepared according to ISO 10993-12 using standardized surface-area-to-extraction-volume ratios, and extracts are generated with appropriate media such as saline, serum-supplemented culture media, or citrated plasma depending on the endpoint being measured.
Testing Items
The test panel is tailored to the device category and intended use, drawing from the five interaction categories defined in ISO 10993-4. Commonly performed test items include the following.
Thrombosis
- Thrombus mass and morphology following exposure
- Flow rate reduction and time to occlusion in dynamic or shunt models
- Scanning electron microscopy assessment of surface thrombus deposition
- Percent luminal occlusion for implanted or shunt-tested devices
Coagulation
- Prothrombin time (PT)
- Activated partial thromboplastin time (APTT)
- Thrombin time (TT) and thrombin generation assays
- Plasma fibrinogen concentration
- Thrombin-antithrombin III complex (TAT) as a marker of thrombin generation
Platelets
- Platelet count and mean platelet volume
- Platelet adhesion to device surfaces
- Platelet aggregation studies
- Platelet activation markers including P-selectin (CD62P) and GP IIb/IIIa by flow cytometry
- Platelet factor 4 (PF4) and beta-thromboglobulin release
Hematology and Hemolysis
- Total and differential leukocyte counts
- Leukocyte activation markers
- Hemoglobin concentration and red blood cell morphology
- Plasma free hemoglobin for hemolysis assessment, reported as a hemolytic index, with materials commonly classified as non-hemolytic below 2 percent, slightly hemolytic between 2 and 5 percent, and hemolytic above 5 percent per ASTM F756 practice
Complement System
- C3a and C5a anaphylatoxins
- Terminal complement complex SC5b-9
- Alternative pathway marker Bb and classical pathway marker C4d
- Total complement activity (CH50) where indicated
Testing Methods
In Vitro Static Methods
Static assays incubate the device or its extract with fresh human or animal blood, plasma, or platelet-rich plasma under controlled temperature and time conditions. Direct-contact and extract-based hemolysis assays expose human or rabbit blood to the test article, after which plasma free hemoglobin is quantified spectrophotometrically. Coagulation assays such as APTT and PT are performed on incubated plasma using automated coagulation analyzers, and complement fragments are quantified by ELISA.
In Vitro Dynamic Flow Methods
Dynamic models better replicate clinical conditions for devices exposed to flowing blood. Recirculating flow loops, Chandler loop systems, and roller-pump circuits expose the test article to blood at defined shear rates and flow rates for a specified duration. These methods allow simultaneous measurement of hemolysis, platelet count reduction, platelet activation, coagulation marker changes, and surface thrombus deposition under physiologically relevant hydrodynamic conditions.
Ex Vivo and In Vivo Thrombogenicity Methods
For high-risk devices, ex vivo arteriovenous shunt studies in animals such as dogs, pigs, or sheep circulate native or minimally anticoagulated blood through the test article, with thrombus formation assessed gravimally and by flow monitoring. In vivo studies implant the device in the intended vascular location for a defined period, followed by autopsy examination, thrombus scoring, and histopathological evaluation. These studies are designed in alignment with animal welfare requirements and applicable national laboratory animal regulations.
Analytical and Microscopy Techniques
Endpoints are measured using validated analytical platforms, including flow cytometry for platelet and leukocyte activation, ELISA for complement and coagulation biomarkers, spectrophotometry for free hemoglobin, automated hematology analyzers for cell counts, gravimetric analysis for thrombus mass, and scanning electron microscopy for surface deposit characterization.
Study Design and Quality Considerations
- Blood source: fresh human donor blood is preferred where feasible; animal blood may be used with scientific justification of species relevance.
- Anticoagulation: citrate is typically used for complement and coagulation assays, heparin for dynamic flow loops, and unanticoagulated blood for thrombosis models where medically relevant.
- Controls: negative control materials such as polyethylene and documented positive hemolytic control materials are included in accordance with ASTM F756, together with blank and baseline blood controls.
- Time points: exposure durations are selected to bracket the intended clinical contact time, often including an early and a late time point.
- Replication: multiple test articles and multiple donors or animals are used to address inherent blood variability.
Applications
Hemocompatibility data supports a wide range of regulatory, development, and quality objectives across the medical device industry.
- Regulatory submissions: biological evaluation files for FDA 510(k), De Novo, and PMA submissions, EU MDR CE technical documentation, NMPA registration dossiers, PMDA applications, and Health Canada licensing.
- Biological safety evaluation: integration into the ISO 10993-1 evaluation plan for any device contacting blood, supporting the overall risk assessment under ISO 14971.
- Research and development: screening of candidate materials, optimization of surface coatings and surface modifications, and comparative benchmarking against predicate devices.
- Change control: justification of material, supplier, manufacturing process, or sterilization changes affecting blood-contacting surfaces.
- Quality control: lot release testing for hemolytic potential and routine monitoring of blood-contacting consumables.
Accredited third-party laboratories with dedicated hemocompatibility capabilities provide study design consultation, protocol development, testing under GLP or ISO/IEC 17025 conditions, and comprehensive reports formatted for submission to global regulatory authorities.
FAQ
Which devices require blood interaction testing?
Any device that directly contacts circulating blood, contacts blood that will return to the patient, or contacts blood at the point of vascular access should be evaluated under ISO 10993-4. The depth of testing scales with contact type and duration, from simple in vitro hemolysis and APTT assays for indirect-contact devices to in vivo thrombogenicity studies for permanent vascular implants.
What is the difference between in vitro, in vivo, and ex vivo testing?
In vitro tests incubate samples with blood or blood components outside a living organism and are suitable for most screening and release purposes. Ex vivo studies use blood circulating through an animal shunt while the animal remains alive, combining realistic flow with controlled observation. In vivo studies implant the device within a living organism to assess thrombosis under true physiological conditions and are generally reserved for the highest-risk devices.
Should human or animal blood be used?
Fresh human donor blood is generally preferred because it best reflects clinical response, particularly for complement and platelet activation assays. However, human blood variability, donor availability, and anticoagulant interactions may justify the use of animal blood, most commonly from rabbits, ovine, porcine, or bovine sources, with documented scientific rationale.
Are there universal pass or fail criteria?
No. ISO 10993-4 defines test categories rather than absolute acceptance limits. Results are interpreted relative to controls and clinically established reference materials, and conclusions are drawn within the framework of the biological evaluation plan and risk management file. The hemolytic index classification from ASTM F756 is one widely applied quantitative benchmark for hemolysis.
How are samples prepared for testing?
Finished devices, device components, or extracts are prepared per ISO 10993-12 using standard surface-area-to-volume ratios and extraction conditions, with sterile products tested as supplied and sterilization effects taken into account. Dynamic tests use intact, flow-ready devices to preserve clinically relevant geometry and shear exposure.
Can existing data replace new testing?
In some cases, documented literature, material characterization, chemical toxicological risk assessment, or testing of a substantially equivalent device may justify a reduced test panel. The rationale must be documented in the biological evaluation file and is subject to regulatory review on a case-by-case basis.
How long does a hemocompatibility study take?
In vitro testing programs typically require several weeks including protocol approval, blood sourcing, testing, and reporting. Ex vivo and in vivo thrombogenicity studies require additional animal ethics approvals and longer timelines, often several months from study design to final report. Early consultation with an accredited third-party laboratory helps align the test plan with the intended regulatory pathway and reduces program delays.